NanomAbs / Immune Pharma, STC Biologics - LARVOL DELTA

A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment. (PubMed, Cancer Lett) - "Recent advances have identified CD47 as a promising therapeutic target, though clinical translation faces challenges due to the complex immunosuppressive tumor microenvironment (TME). Here we developed an innovative oncolytic vaccinia virus platform expressing an anti-CD47 nanobody (OVV-aCD47nb), designed to simultaneously target tumor cells and modulate immune responses."

Journal • Oncology • Pancreatic Cancer • Solid Tumor • CD47

Anti-ETX Nanobodies: Innovative Tools for MS Research, Diagnosis and Therapy (MSMilan 2023) - "On the therapeutic front, the nanomAbs demonstrated remarkable efficacy by completely abolishing the acute toxicity of ETX to human red blood cells in an ex-vivo model, showing their potential as future biologics for both acute treatment and prophylaxis of RRMS relapses. With this study we have successfully developed innovative nanobody-based biologics that can both sensitively detect and neutralize ETX, a potential triggering factor in RRMS. Our findings pave the way for a deeper understanding of the ETX-MS connection and open new avenues for targeted diagnostic and therapeutic interventions."

CNS Disorders • Multiple Sclerosis